Infectious Disease Clinical Trials

Ri-CoDIFy 2

The purpose of this study is to assess how safe an investigational drug, ridinilazole, is and how well it works at treating Clostridium difficile (CDI) and stopping it from returning over a period of 3 months. The study will compare ridinilazole to vancomycin, which is an existing antibiotic often used to treat CDI.

Currently enrolling

Who may be eligible to participate?
Subjects 18 years of age and older with signs and symptoms of CDI including diarrhea. Eligible subjects must have the presence of either toxin A and/or B of CDI in the stool determined by a positive free toxin test. Other inclusion and exclusion criteria apply.

What does participation involve?
Subjects will be asked to participate in this study for about 100 days (about 3 months), which includes a screening visit, a telephone check-in, and 5 other in-clinic visits. Subjects may be asked to attend additional visits to check for a new CDI (for example, if diarrhea returns), and you may be contacted additional times by telephone.

Investigator: Francis X. Riedo, MD, EvergreenHealth Infectious Disease Care

For more information, contact the EvergreenHealth Research Services hotline at 425-899-5385 or email